Masimo (NASDAQ:MASI) Receives “Hold” Rating from Needham & Company LLC

Masimo (NASDAQ:MASIGet Free Report)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company boosted their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Piper Sandler boosted their price objective on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $179.67.

Read Our Latest Report on MASI

Masimo Trading Up 2.2 %

NASDAQ:MASI opened at $176.07 on Wednesday. The stock has a fifty day moving average price of $169.44 and a 200 day moving average price of $140.91. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a 12-month low of $101.61 and a 12-month high of $180.97. The firm has a market cap of $9.43 billion, a PE ratio of 121.43 and a beta of 1.01.

Masimo (NASDAQ:MASIGet Free Report) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 earnings per share. Sell-side analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. NBC Securities Inc. grew its holdings in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the last quarter. UMB Bank n.a. lifted its holdings in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont purchased a new stake in shares of Masimo during the fourth quarter worth about $33,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Masimo by 136.5% in the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 269 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

(Get Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

See Also

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.